At Thomson Reuters Text Metadata Services group, we are leading the industry in AI machine learning based metadata products, focusing on NLP and knowledge-graph solutions. Our products organize Thomson Reuters' and Clients own, unstructured content feeding customers with significant insights extracted programmatically from narrative text. We are looking for a talented and experienced Senior Big Data Engineer to add significant capability to our products, Thomson Reuters Intelligent Tagging (TRIT) and Knowledge Graph (TRKG). This position is full time and based at our Singapore office. This role sits within our Financial & Risk ("F&R") business.

These and many other fascinating insights are from CB Insight's report, Google Strategy Teardown (PDF, 49 pp., opt-in). The report explores how Alphabet, Google's parent company is relying on Artificial Intelligence (AI) and machine learning to capture new streams of revenue in enterprise cloud computing and services. Also, the report looks at how Alphabet can combine search, AI, and machine learning to revolutionise logistics, healthcare, and transportation. It's a thorough teardown of Google's potential acquisitions, strategic investments, and partnerships needed to maintain search dominance while driving revenue from new markets. CB Insights found Google is experiencing rising TAC in their core ad and search businesses.

The companies are UiPath Inc., Blue Prism Group PRSM 3.81% PLC and Automation Anywhere Inc. They were all founded in 2005 or earlier, but it wasn't until the past few years that they took off after hitting on their current business automating simple back-office tasks and dubbing it "robotic process automation." UiPath on Monday completed a new funding round at a $3 billion valuation, said a person familiar with the process, six months after a prior round valued it at $1.1 billion. In July, rival Automation Anywhere raised its first round of financing at a $1.8 billion valuation. Shares in Blue Prism, a public company in the U.K., have risen nearly 30 times since they were listed in March 2016.

The maverick of personal computing is looking for its next big thing in spaces like healthcare, AR, and autonomous cars, all while keeping its lead in consumer hardware. With an uphill battle in AI, slowing growth in smartphones, and its fingers in so many pies, can Apple reinvent itself for a third time? Get the detailed analysis on Apple's trove of patents, acquisitions, earnings calls, recent product releases, and organizational structure. In many ways, Apple remains a company made in the image of Steve Jobs: iconoclastic and fiercely product focused. But today, Apple is at a crossroads. Under CEO Tim Cook, Apple's ability to seize on emerging technology raises many new questions. Looking for the next wave, Apple is clearly expanding into augmented reality and wearables with the Apple Watch and AirPods wireless headphones. Apple's HomePod speaker system is poised to expand Siri's footprint into the home and serve as a competitor to Amazon's blockbuster Echo device and accompanying virtual assistant Alexa. But the next "big one" -- a success and growth driver on the scale of the iPhone -- has not yet been determined. Will it be augmented reality, auto, wearables? Apple is famously secretive, and a cloud of hearsay and gossip surrounds the company's every move. Apple is believed to be working on augmented reality headsets, connected car software, transformative healthcare devices and apps, as well as smart home tech, and new machine learning applications. We dug through Apple's trove of patents, acquisitions, earnings calls, recent product releases, and organizational structure for concrete hints at how the company will approach its next self-reinvention. Given Apple's size and prominence, we won't be covering every aspect of its business or rehashing old news. There's strong evidence Apple is once again actively "cannibalizing itself," putting massive resources behind consumer tech that will render its own iPhone obsolete. Augmented reality is the company's biggest bet.

It may be a long time before you can own a truly self-driving car. But chipmakers are placing bets that you will. On Tuesday, the Japanese chipmaker Renesas, the second-largest provider of semiconductors for the automotive industry, said it will acquire San Jose based chipmaker Integrated Device Technology (IDT) for $6.7 billion, in part to prepare for autonomous vehicles. IDT has not historically provided chips for cars, but it does have sensor and wireless technologies that could help Renesas compete in the market for chips for autonomous vehicles. "Renesas and IDT have complementary technologies," says Objective Analysis analyst Jim Handy.

The trio of phones will boast other features, such as facial-recognition technology, but their display size stands out--their average screen area, without accounting for a facial-recognition system that juts into the top of the display, is 23% larger than last year's three new phones and 28% bigger than the two models unveiled in 2016. Note: Screens on iPhone X and newer have facial-recognition systems that cut into the display. At a time when people are buying fewer new phones, bigger size brings two advantages. It helps Apple buoy prices and profit margins because it can sell larger phones at a greater markup than it pays suppliers for the larger screens. And it encourages people to use their phones more, helping momentum of Apple's services business, which includes app-store sales and subscriptions to video services like Netflix and HBO.

Corporate earnings are set to rise more than 20%. Productivity gains in excess of 5% of global GDP are possible. And $650 billion of new industrial spending is likely. It examines how advances in information technology are tilting the landscape. Spoiler alert: Investors need to get ready.

Graphics processor maker NVIDIA Corporation (NASDAQ:NVDA) recently reported its second-quarter fiscal 2019 results, with some fantastic outcomes. The company's total sales were up 40% from the year-ago quarter to $3.12 billion, which outpaced analysts' consensus estimate of $3.10 billion. NVIDIA's earnings of $1.76 per share also surpassed Wall Street's expectations of $1.66 per share and were up 91% year over year. Management has done a fantastic job of growing the company's top line, and the second quarter was no exception -- sales from the company's data center, gaming, professional visualization, and automotive segments all set records. To understand NVIDIA's growth and what investors can expect in the months ahead, we have to look beyond the numbers, though.

Above the Trend Line: your industry rumor central is a recurring feature of insideBIGDATA. In this column, we present a variety of short time-critical news items grouped by category such as M&A activity, people movements, funding news, financial results, industry alignments, customer wins, rumors and general scuttlebutt floating around the big data, data science and machine learning industries including behind-the-scenes anecdotes and curious buzz. Our intent is to provide you a one-stop source of late-breaking news to help you keep abreast of this fast-paced ecosystem. We're working hard on your behalf with our extensive vendor network to give you all the latest happenings. Be sure to Tweet Above the Trend Line articles using the hashtag: #abovethetrendline.

The healthcare ecosystem is experiencing seismic shifts stemming from new socio-economic realities, a new science landscape, and the consumerization of healthcare--all being rapidly pushed forward by advances in data, digital and technology. Incumbents have a tremendous opportunity to lead the market into a new era focused on truly delivering more effective, efficient and affordable healthcare. AI can help you generate insights from vast amounts of data in real-time, creating new intelligence that can power innovative patient treatments, better care, more efficient operations and new business growth. And as one of the largest health and life sciences professional services providers globally, we can deliver increased speed-to-value through innovative contracting, partnerships, and scalable AI- and analytics-powered services. Expand business growth through improved medication adherence and patient retention (e.g., through our Patient Experience Manager)